Enanta Pharmaceuticals (ENTA) Stock Overview

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

ENTA Stock Information

Symbol

ENTA

Address

500 Arsenal StreetWatertown, MA 02472United States

Founded

Trading hours

9:30 AM - 4:00 PM ET

Website

https://www.enanta.com

Country

🇺🇸 United States

Phone Number

617 607 0800

Enanta Pharmaceuticals (ENTA) Price Chart

Enanta Pharmaceuticals Overview: Key Details and Summary

Stock data	2023	Change
Price	$6.28	N/A
Market Cap	$131.69M	N/A
Shares Outstanding	20.97M	1.78%
Employees	145.00	N/A
Shareholder Equity	216.74M	-32.55%

Valuation	2023	Change
P/E Ratio	-0.98	N/A
P/S Ratio	1.66	N/A
P/B Ratio	0.61	N/A

Growth	2023	Change
Return on Equity	-0.6174	N/A

Earnings	2023	Change
Revenue	$79.20M	N/A
Earnings	-$133.82M	N/A
EPS	-6.38	N/A
Earnings Yield	-1.02	N/A
Operating Margin	-1.73	N/A
Net income margin	-1.69	N/A

Financial Strength	2023	Change
Total Assets	$462.27M	N/A
Total Debt	$26.51M	N/A
Cash on Hand	$369.91M	N/A
Debt to Equity	$1.13	573.20%
Cash to Debt	$13.95	41.42%
Current Ratio	$6.73	-35.57%